EE05169B1 - Asendatud oksasolidinoonid ja nende kasutamine - Google Patents

Asendatud oksasolidinoonid ja nende kasutamine

Info

Publication number: EE05169B1
Authority: EE; Estonia
Prior art keywords: substituted oxazolidinones; oxazolidinones; substituted
Prior art date: 1999-12-24

Application number

EEP200200341A

Other languages

English (en)

Inventor

Straub Alexander

Lampe Thomas

Pohlmann Jens

Rhrig Susanne

Perzborn Elisabeth

Schlemmer Karl-Heinz

Pernerstorfer Josef

Original Assignee

Bayer Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-24

Filing date

2000-12-11

Publication date

2009-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7934434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05169(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-12-11 Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft

2003-10-15 Publication of EE200200341A publication Critical patent/EE200200341A/et

2009-06-15 Publication of EE05169B1 publication Critical patent/EE05169B1/et

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

EEP200200341A 1999-12-24 2000-12-11 Asendatud oksasolidinoonid ja nende kasutamine EE05169B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19962924A DE19962924A1 (de)	1999-12-24	1999-12-24	Substituierte Oxazolidinone und ihre Verwendung
PCT/EP2000/012492 WO2001047919A1 (de)	1999-12-24	2000-12-11	Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung

Publications (2)

Publication Number	Publication Date
EE200200341A EE200200341A (et)	2003-10-15
EE05169B1 true EE05169B1 (et)	2009-06-15

Family

ID=7934434

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200200341A EE05169B1 (et)	1999-12-24	2000-12-11	Asendatud oksasolidinoonid ja nende kasutamine

Country Status (50)

Country	Link
US (8)	US7157456B2 (et)
EP (2)	EP1261606B1 (et)
JP (2)	JP4143297B2 (et)
KR (3)	KR20070094672A (et)
CN (3)	CN1262551C (et)
AR (1)	AR032436A1 (et)
AT (1)	ATE289605T1 (et)
AU (2)	AU775126C (et)
BE (1)	BE2008C046I2 (et)
BG (1)	BG65683B1 (et)
BR (1)	BR0017050B1 (et)
CA (1)	CA2396561C (et)
CO (1)	CO5251440A1 (et)
CU (2)	CU23208A3 (et)
CY (2)	CY2008019I1 (et)
CZ (1)	CZ301432B6 (et)
DE (3)	DE19962924A1 (et)
DK (2)	DK1261606T3 (et)
DO (2)	DOP2000000114A (et)
EE (1)	EE05169B1 (et)
ES (2)	ES2237497T3 (et)
FR (1)	FR08C0051I2 (et)
GT (1)	GT200000216A (et)
HK (3)	HK1057556A1 (et)
HN (1)	HN2000000267A (et)
HR (2)	HRP20020617B1 (et)
HU (1)	HU226522B1 (et)
IL (2)	IL149896A0 (et)
LT (1)	LTC1261606I2 (et)
LU (1)	LU91497I2 (et)
MA (1)	MA25646A1 (et)
MX (1)	MXPA02006241A (et)
MY (1)	MY140488A (et)
NL (1)	NL300370I2 (et)
NO (4)	NO323699B1 (et)
NZ (2)	NZ519730A (et)
PE (1)	PE20010963A1 (et)
PL (2)	PL200413B1 (et)
PT (2)	PT1261606E (et)
RU (1)	RU2297415C2 (et)
SG (1)	SG130939A1 (et)
SI (2)	SI1526132T1 (et)
SK (1)	SK287272B6 (et)
SV (1)	SV2002000245A (et)
TR (2)	TR200401314T2 (et)
TW (2)	TWI226330B (et)
UA (1)	UA73339C2 (et)
UY (1)	UY34152A (et)
WO (1)	WO2001047919A1 (et)
ZA (1)	ZA200204188B (et)

Families Citing this family (248)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19962924A1 (de)	1999-12-24	2001-07-05	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
US6710058B2 (en) *	2000-11-06	2004-03-23	Bristol-Myers Squibb Pharma Company	Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10105989A1 (de) *	2001-02-09	2002-08-14	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) *	2001-06-20	2003-01-02	Bayer Ag	Kombinationstherapie substituierter Oxazolidinone
US7390825B1 (en)	2001-10-18	2008-06-24	Board Of Trustees Of Michigan State University	Process for the preparation of oxazolidinones and method of use thereof
DE10152460A1 (de) *	2001-10-24	2003-05-08	Bayer Ag	Stents
JP2005512975A (ja)	2001-10-25	2005-05-12	アストラゼネカアクチボラグ	抗菌薬として有用なイソキサゾリン誘導体
WO2003078448A1 (en)	2002-03-13	2003-09-25	Signum Biosciences, Inc.	Modulation of protein methylation and phosphoprotein phosphate
DE10300111A1 (de)	2003-01-07	2004-07-15	Bayer Healthcare Ag	Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US7012088B2 (en)	2003-02-24	2006-03-14	Pharmacia & Upjohn Company	Indolone oxazolidinones and derivatives thereof
DE10322469A1 (de) *	2003-05-19	2004-12-16	Bayer Healthcare Ag	Heterocyclische Verbindungen
DE10336716A1 (de) *	2003-08-11	2005-03-10	Merck Patent Gmbh	Verfahren zur Herstellung von N-Aryl-morpholinonen
DE10342570A1 (de) *	2003-09-15	2005-04-14	Bayer Healthcare Ag	Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
DE10355461A1 (de)	2003-11-27	2005-06-23	Bayer Healthcare Ag	Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) *	2004-01-15	2005-08-04	Bayer Healthcare Ag	Herstellverfahren
US7371743B2 (en)	2004-02-28	2008-05-13	Boehringer Ingelheim International Gmbh	Carboxylic acid amides, the preparation thereof and their use as medicaments
EP1571154A1 (en) *	2004-03-03	2005-09-07	Aventis Pharma Deutschland GmbH	Beta-aminoacid-derivatives as factor Xa inhibitors
US7550499B2 (en)	2004-05-12	2009-06-23	Bristol-Myers Squibb Company	Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
BRPI0510019A (pt) *	2004-05-13	2007-09-25	Boehringer Ingelheim Int	amidas de ácido tiofenocarboxìlico substituìdas, sua preparação e seu uso como medicamento
JP2007537179A (ja) *	2004-05-13	2007-12-20	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	置換チオフェン−２−カルボン酸アミド、その製法及び薬物としての使用
US7696352B2 (en) *	2004-06-18	2010-04-13	Millennium Pharmaceuticals, Inc.	Factor Xa inhibitors
KR101195801B1 (ko) *	2004-06-18	2012-11-05	밀레니엄 파머슈티컬스 인코퍼레이티드	Ｘａ 인자 억제제
DE602004020812D1 (de) *	2004-07-20	2009-06-04	Symed Labs Ltd	Neue zwischenprodukte für linezolid und verwandte verbindungen
PE20060619A1 (es) *	2004-07-29	2006-07-11	Ferrer Int	Derivados de oxazolidinona como antibacterianos
DE102004047840A1 (de) *	2004-09-29	2006-03-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
DE102004050283A1 (de) *	2004-10-15	2006-04-27	Lanxess Deutschland Gmbh	4-Aminophenyl-morpholinon-Derivate und deren Herstellung
US7645755B2 (en)	2004-10-22	2010-01-12	Janssen Pharmaceutical N.V.	Inhibitors of c-fms kinase
NZ555289A (en)	2004-10-22	2010-10-29	Janssen Pharmaceutica Nv	Inhibitors of c-fms kinase
DE102004062475A1 (de) *	2004-12-24	2006-07-06	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1954696B1 (en)	2005-01-19	2011-02-23	Bristol-Myers Squibb Company	2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
EP1685841A1 (en) *	2005-01-31	2006-08-02	Bayer Health Care Aktiengesellschaft	Prevention and treatment of thromboembolic disorders
WO2006084033A1 (en)	2005-02-03	2006-08-10	Signum Biosciences, Inc.	Compositions and methods for enhancing cognitive function
US7923041B2 (en)	2005-02-03	2011-04-12	Signum Biosciences, Inc.	Compositions and methods for enhancing cognitive function
DE102005018690A1 (de) *	2005-04-22	2006-10-26	Bayer Healthcare Ag	Imino-oxazolidine und ihre Verwendung
US20060281788A1 (en) *	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
KR20080027890A (ko)	2005-06-27	2008-03-28	브리스톨-마이어스 스큅 컴퍼니	혈전성 증상의 치료에 유용한 ｐ2ｙ1 수용체의 ｎ-연결헤테로시클릭 길항제
ATE485269T1 (de)	2005-06-27	2010-11-15	Bristol Myers Squibb Co	C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
WO2007002634A1 (en)	2005-06-27	2007-01-04	Bristol-Myers Squibb Company	Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7816382B2 (en)	2005-06-27	2010-10-19	Bristol-Myers Squibb Company	Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
PE20070171A1 (es) *	2005-06-30	2007-03-08	Boehringer Ingelheim Int	GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
WO2007007588A1 (ja) *	2005-07-08	2007-01-18	Ono Pharmaceutical Co., Ltd.	平面性を有する環状基を母核とする化合物
US20070032473A1 (en) *	2005-07-19	2007-02-08	Kai Gerlach	Substituted amides and their use as medicaments
AR057976A1 (es) *	2005-08-29	2008-01-09	Boehringer Ingelheim Int	Biarilos sustituidos y su uso como medicamentos.
DE102005045518A1 (de) *	2005-09-23	2007-03-29	Bayer Healthcare Ag	2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
RU2429236C2 (ru) *	2005-10-04	2011-09-20	Байер Шеринг Фарма Акциенгезельшафт	Новая полиморфная форма и аморфная форма 5-хлор-n-({(5s)-2-оксо-3-[4-(3-оксо-4-морфолинил)-фенил]-1, 3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида
DE102005047564A1 (de) *	2005-10-04	2007-05-31	Bayer Healthcare Ag	Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
DE102005047561A1 (de)	2005-10-04	2007-04-05	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005047558A1 (de) *	2005-10-04	2008-02-07	Bayer Healthcare Ag	Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005048824A1 (de) *	2005-10-10	2007-04-12	Bayer Healthcare Ag	Behandlung und Prophylaxe von Mikroangiopathien
CN101340909B (zh)	2005-10-18	2012-01-11	詹森药业有限公司	抑制flt3激酶的方法
US7962847B2 (en) *	2005-10-20	2011-06-14	International Business Machines Corporation	Method for providing dynamic process step annotations
DE102005052174A1 (de)	2005-11-02	2007-06-06	Bayer Healthcare Ag	Phenylen-bis-oxazolidin-Derivate und ihre Verwendung
JP2007154330A (ja) *	2005-12-01	2007-06-21	Nippon Paper Industries Co Ltd	印刷用塗工紙
CA2635262C (en) *	2005-12-30	2011-08-16	Merck & Co., Inc.	1, 3-oxazolidin-2-one derivatives useful as cetp inhibitors
DE102006007146A1 (de)	2006-02-16	2007-08-23	Bayer Healthcare Ag	Aminoacyl-Prodrugs
EP2009012B1 (en)	2006-03-31	2014-06-25	Research Foundation Itsuu Laboratory	Novel compound having heterocyclic ring
NZ572070A (en)	2006-04-20	2011-09-30	Janssen Pharmaceutica Nv	Inhibitors of c-fms kinase
PL2021335T3 (pl)	2006-04-20	2011-10-31	Janssen Pharmaceutica Nv	Związki heterocykliczne jako inhibitory kinazy C-FMS
US8697716B2 (en) *	2006-04-20	2014-04-15	Janssen Pharmaceutica Nv	Method of inhibiting C-KIT kinase
EP2687516A1 (en)	2006-04-20	2014-01-22	Janssen Pharmaceutica N.V.	Inhibitors of C-FMS Kinase
EP2397138B1 (en)	2006-04-20	2013-12-11	Janssen Pharmaceutica NV	Aromatic amide derivatives as C-KIT kinase inhibitors
CA2651303A1 (en)	2006-05-05	2007-11-15	Millennium Pharmaceuticals, Inc.	Factor xa inhibitors
DE102006025314A1 (de) *	2006-05-31	2007-12-06	Bayer Healthcare Ag	Arylsubstituierte Heterozyklen und ihre Verwendung
DE102006025319A1 (de) *	2006-05-31	2007-12-06	Bayer Healthcare Aktiengesellschaft	Substituierte Heterozyklen und ihre Verwendung
DE102006034916A1 (de) *	2006-07-28	2008-01-31	Bayer Healthcare Ag	Beschichtung künstlicher Oberflächen von medizinischen Hilfsmitteln und Geräten sowie Reinigung und/oder Vorbehandlung von Kathetern und anderen medizinischen Hilfsmitteln und Geräten
DE102006039589A1 (de) *	2006-08-24	2008-03-06	Bayer Healthcare Ag	Aminoacyl-Prodrugs II
US7960569B2 (en)	2006-10-17	2011-06-14	Bristol-Myers Squibb Company	Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE102006051625A1 (de) *	2006-11-02	2008-05-08	Bayer Materialscience Ag	Kombinationstherapie substituierter Oxazolidinone
US8410155B2 (en)	2006-12-15	2013-04-02	Bristol-Myers Squibb Company	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors
PE20081775A1 (es)	2006-12-20	2008-12-18	Bristol Myers Squibb Co	Compuestos macrociclicos como inhibidores del factor viia
US20080293704A1 (en) *	2007-01-05	2008-11-27	Millennium Pharmaceuticals, Inc.	FACTOR Xa INHIBITORS
JPWO2008120655A1 (ja) *	2007-03-30	2010-07-15	株式会社医薬分子設計研究所	Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有するオキサゾリジノン誘導体
DE102007018662A1 (de)	2007-04-20	2008-10-23	Bayer Healthcare Ag	Oxazolidinone zur Behandlung und Prophylaxe von pulmonaler Hypertonie
CN101663293B (zh)	2007-04-23	2013-07-31	塞诺菲-安万特股份有限公司	作为p2y12拮抗剂的喹啉-甲酰胺衍生物
WO2008140220A1 (en) *	2007-05-09	2008-11-20	Legochem Bioscience Ltd.	Fxa inhibitors with cyclic amidines as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof
KR101009594B1 (ko)	2007-05-09	2011-01-20	주식회사 레고켐 바이오사이언스	Ｐ4 위치에 사이클릭 아미딘을 가지는 ＦＸａ 저해제, 이의유도체, 제조방법 및 이를 함유하는 의약 조성물
DE102007028406A1 (de) *	2007-06-20	2008-12-24	Bayer Healthcare Ag	Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) *	2007-06-20	2008-12-24	Bayer Healthcare Ag	Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) *	2007-06-20	2008-12-24	Bayer Healthcare Ag	Substituierte Oxazolidinone und ihre Verwendung
DE102007028318A1 (de)	2007-06-20	2008-12-24	Bayer Healthcare Ag	Oxazolidinone zur Behandlung und Prophylaxe von Sepsis
DE102007028320A1 (de) *	2007-06-20	2008-12-24	Bayer Healthcare Ag	Substituierte Oxazolidinone und ihre Verwendung
DE102007037373A1 (de)	2007-08-06	2009-02-19	Schebo Biotech Ag	Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie
WO2009018807A1 (de) *	2007-08-06	2009-02-12	Schebo Biotech Ag	Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie
US20090076264A1 (en) *	2007-09-15	2009-03-19	Protia, Llc	Deuterium-enriched rivaroxaban
EP2233484A3 (en)	2007-10-02	2012-04-04	Research Foundation Itsuu Laboratory	Oxazolidinone derivatives having a 7-membered heterocyclic ring
JO3240B1 (ar)	2007-10-17	2018-03-08	Janssen Pharmaceutica Nv	c-fms مثبطات كيناز
EP2220079A2 (en) *	2007-11-15	2010-08-25	Boehringer Ingelheim International GmbH	Substituted amides, manufacturing and use thereof as medicaments
KR20110010689A (ko) *	2007-12-11	2011-02-07	바이엘 쉐링 파마 악티엔게젤샤프트	심부전의 치료 및/또는 예방을 위한 옥사졸리디논
EP2238128B1 (en)	2007-12-26	2012-08-22	Sanofi	Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AU2009239430B2 (en)	2008-04-21	2015-01-22	Signum Biosciences, Inc.	Compounds, compositions and methods for making the same
DE102008028071A1 (de) *	2008-06-12	2009-12-17	Bayer Schering Pharma Aktiengesellschaft	Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure
EP2138178A1 (en)	2008-06-28	2009-12-30	Bayer Schering Pharma Aktiengesellschaft	Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
KR100898361B1 (ko) *	2008-07-03	2009-05-20	주식회사 레고켐 바이오사이언스	Ｐ4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 ＦＸａ 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물
EP2140866A1 (en) *	2008-07-04	2010-01-06	Bayer Schering Pharma Aktiengesellschaft	Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract
US20110300214A1 (en)	2008-07-08	2011-12-08	Ratiopharm Gmbh	Pharmaceutical compositions comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid
KR101023174B1 (ko) *	2008-09-24	2011-03-18	주식회사 레고켐 바이오사이언스	사이클릭 아미독심 또는 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
US20100168111A1 (en) *	2008-12-31	2010-07-01	Apotex Pharmachem Inc.	Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
MY161598A (en) *	2009-01-30	2017-04-28	Glaxosmithkline Llc	Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US7816355B1 (en) *	2009-04-28	2010-10-19	Apotex Pharmachem Inc	Processes for the preparation of rivaroxaban and intermediates thereof
LT2442799T (lt)	2009-06-18	2016-12-27	Krka, Tovarna Zdravil, D.D., Novo Mesto	Kieta farmacinė kompozicija, apimanti rivaroksabaną
EP2266541A1 (en)	2009-06-18	2010-12-29	Krka Tovarna Zdravil, D.D., Novo Mesto	Solid pharmaceutical composition comprising rivaroxaban
KR101037052B1 (ko)	2009-07-08	2011-05-26	주식회사 레고켐 바이오사이언스	5-클로로-ｎ-(((5ｓ)-2-옥소-3-(4-(5,6-디하이드로-1,2,4-트리아진-1(4ｈ)-일)페닐)-1,3-옥사졸리딘-5-일)메틸)티오펜-2-카르복사미드 유도체의 제조방법 및 그 제조중간체
KR101037051B1 (ko) *	2009-07-08	2011-05-26	주식회사 레고켐 바이오사이언스	(ｓ)-5-클로로-ｎ-((3-(4-(5,6-다이하이드로-4ｈ-1,2,4-옥사다이아진-3-일)페닐)-2-옥소옥사졸리딘-5-일)메틸)싸이오펜-2-카르복사미드 유도체의 제조방법
PL2459555T3 (pl)	2009-07-31	2022-03-28	Krka, D.D., Novo Mesto	Sposoby krystalizacji rywaroksabanu
EP2308472A1 (en)	2009-10-06	2011-04-13	ratiopharm GmbH	Pharmaceutical compositions comprising rivaroxaban
WO2011042156A1 (en)	2009-10-06	2011-04-14	Ratiopharm Gmbh	Pharmaceutical compositions comprising rivaroxaban
WO2011061760A1 (en) *	2009-11-18	2011-05-26	Cadila Healthcare Limited	Novel antithrombotic agents
WO2011084652A2 (en) *	2009-12-17	2011-07-14	Millennium Pharmaceuticals, Inc.	Salts and crystalline forms of a factor xa inhibitor
US8742120B2 (en)	2009-12-17	2014-06-03	Millennium Pharmaceuticals, Inc.	Methods of preparing factor xa inhibitors and salts thereof
CN102822167A (zh) *	2010-01-04	2012-12-12	埃南蒂亚有限公司	用于制备利伐沙班的方法及其中间体
EP2354128A1 (en)	2010-02-10	2011-08-10	Sandoz Ag	Method for the preparation of rivaroxaban
TWI577665B (zh)	2010-02-11	2017-04-11	必治妥美雅史谷比公司	作為因子ｘｉａ抑制劑之巨環類
EA015918B1 (ru)	2010-03-03	2011-12-30	Дмитрий Геннадьевич ТОВБИН	УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
DE102010018299A1 (de)	2010-04-23	2011-10-27	Archimica Gmbh	Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on
DE102010028362A1 (de)	2010-04-29	2011-11-03	Bayer Schering Pharma Aktiengesellschaft	Herstellverfahren
KR101799429B1 (ko) *	2010-05-03	2017-11-21	에스케이바이오팜 주식회사	신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
EP2388260A1 (de)	2010-05-21	2011-11-23	Archimica GmbH	Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors
CN102311400A (zh) *	2010-06-29	2012-01-11	翔真生物科技股份有限公司	制备5-左旋-氨甲基-3-芳基-2-恶唑烷酮类的方法
EP2404920A1 (en)	2010-07-06	2012-01-11	Sandoz AG	Crystalline form of Rivaroxaban dihydrate
US20130253187A1 (en)	2010-09-14	2013-09-26	Medichem, S.A.	Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative
CZ2010714A3 (cs)	2010-09-30	2012-04-11	Farmak, A. S.	Zpusob výroby 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinyl)fenyl]-1,3oxazolidin-5-yl}methyl)-1H-isoindol-1,3(2H)-dionu ve vysoké optické cistote
AU2010362639B2 (en) *	2010-10-18	2016-10-27	Apotex Pharmachem Inc.	Processes for the preparation of Rivaroxaban and intermediates thereof
CN102464658B (zh) *	2010-11-03	2014-04-16	天津药物研究院	噁唑烷酮衍生物及其制备方法和用途
DE102010063127A1 (de)	2010-12-15	2012-06-21	Bayer Schering Pharma Aktiengesellschaft	Flüssige, oral applizierbare pharmazeutische Zusammensetzungen enthaltend 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US20140050743A1 (en)	2011-01-19	2014-02-20	Bayer Intellectual Property Gmbh	Binding proteins to inhibitors of coagulation factors
CN102199150A (zh) *	2011-04-01	2011-09-28	中国药科大学	光学活性噁唑烷酮类衍生物及其制备方法与在制药中的用途
EP2697209B1 (en)	2011-04-11	2015-09-23	Sandoz AG	Method for the preparation of substituted oxazolidinones
EP2705028B1 (en) *	2011-05-06	2019-08-21	Egis Gyógyszergyár Zrt.	Process for the preparation of a rivaroxaban and intermediates formed in said process
WO2012156983A1 (en) *	2011-05-16	2012-11-22	Symed Labs Limited	Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
ES2395304B1 (es) *	2011-05-20	2014-01-16	Interquim, S.A.	Procedimiento de obtención de una tiofen-2-carboxamida.
CN102796092B (zh) *	2011-05-24	2015-04-08	北大方正集团有限公司	噁唑烷酮衍生物及其制备方法和应用
CN102796091A (zh) *	2011-05-24	2012-11-28	北大方正集团有限公司	取代的噁唑烷酮化合物及其制备方法和应用
CN102320988B (zh) *	2011-06-03	2014-04-09	中国科学院上海有机化学研究所	4-(4-氨基苯基)-3-吗啉酮中间体酰胺、合成方法和用途
CN102827154B (zh)	2011-06-14	2015-04-22	上海科胜药物研发有限公司	一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法
TW201311689A (zh)	2011-08-05	2013-03-16	必治妥美雅史谷比公司	作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh)	2011-08-05	2013-05-16	必治妥美雅史谷比公司	作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
EP2753619A2 (en)	2011-09-08	2014-07-16	Cadila Healthcare Limited	Processes and intermediates for preparing rivaroxaban
EP2573084A1 (en)	2011-09-22	2013-03-27	Enantia, S.L.	Novel crystalline forms of rivaroxaban and processes for their preparation
WO2013046211A1 (en) *	2011-09-27	2013-04-04	Symed Labs Limited	Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide and intermediates thereof
WO2013053739A1 (en)	2011-10-10	2013-04-18	Laboratorios Lesvi, S. L.	Process for preparing factor xa inhibitors
HU230734B1 (hu)	2011-10-10	2017-12-28	EGIS Gyógyszergyár Nyrt	Gyógyászati készítmény előállítására alkalmazható rivaroxaban kokristályok
WO2013054275A1 (en) *	2011-10-11	2013-04-18	Council Of Scientific & Industrial Research	Sila analogs of oxazolidinone derivatives and synthesis thereof
JP6033317B2 (ja)	2011-10-14	2016-11-30	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	第ｘｉａ因子阻害剤としての置換テトラヒドロイソキノリン化合物
EP3309148A1 (en)	2011-10-14	2018-04-18	Bristol-Myers Squibb Company	Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
IN2014CN02805A (et)	2011-10-14	2015-07-03	Bristol Myers Squibb Co
CN102408420B (zh) *	2011-10-19	2014-10-22	汕头经济特区鮀滨制药厂	一种利伐沙班及其中间体的制备方法以及中间体化合物
WO2013121436A2 (en)	2012-02-06	2013-08-22	Megafine Pharma (P) Ltd	A process for preparation of rivaroxaban and intermediates thereof
CZ2012111A3 (cs)	2012-02-16	2013-08-28	Zentiva, K.S.	Zpusob prípravy rivaroxabanu zalozený na vyuzití (S)-epichlorhydrinu
CZ2012114A3 (cs)	2012-02-17	2013-02-20	Zentiva, K.S.	Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu
CN103288814B (zh)	2012-02-24	2016-07-06	国药集团国瑞药业有限公司	一种利伐沙班中间体的制备方法
WO2013151719A2 (en) *	2012-04-05	2013-10-10	Scifluor Life Sciences, Llc	Fluorinated oxazolidinone derivatives
US9562040B2 (en)	2012-04-06	2017-02-07	Indiana University Research And Technology Corporation	Processes for preparing Rivaroxaban
IN2014DN09450A (et)	2012-04-16	2015-07-17	Ranbaxy Lab Ltd
CN104487436B (zh)	2012-05-02	2017-05-24	信谊实验室有限公司	使用中间产物制备利伐沙班的改良方法
EP2855465A1 (en) *	2012-05-24	2015-04-08	Ranbaxy Laboratories Limited	Process for the preparation of rivaroxaban
CN102746287B (zh) *	2012-06-21	2014-05-28	成都苑东药业有限公司	一种恶唑烷酮化合物及其制备方法
UY34856A (es)	2012-07-03	2013-12-31	Bayer Pharma AG	Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
CN102757424B (zh) *	2012-07-09	2014-10-15	云南大学	2-苄基取代苯并呋喃—咪唑盐类化合物及其制备方法
CN102746288B (zh) *	2012-07-24	2015-04-08	常州制药厂有限公司	一种抗凝血药及其关键中间体的制备方法
AR091981A1 (es)	2012-08-03	2015-03-11	Bristol Myers Squibb Co	Dihidropiridona p1 como inhibidores del factor xia
LT2882734T (lt)	2012-08-03	2016-12-12	Bristol-Myers Squibb Company	Dihidropiridonai, kaip xia faktoriaus slopikliai
ES2608628T3 (es)	2012-08-07	2017-04-12	Janssen Pharmaceutica Nv	Procedimiento para la preparacion de derivados de ester heterociclicos
JOP20180012A1 (ar)	2012-08-07	2019-01-30	Janssen Pharmaceutica Nv	عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
CN103626749A (zh) *	2012-08-21	2014-03-12	苏州泽璟生物制药有限公司	取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
US20150218145A1 (en)	2012-09-26	2015-08-06	Ranbaxy Laboratories Limited	Process for the preparation of rivaroxaban
CN103864773B (zh) *	2012-12-13	2017-03-15	北京藏卫信康医药研发有限公司	利伐沙班及其中间体的制备方法
SI3309158T1 (sl)	2012-12-21	2023-12-29	Krka, Tovarna Zdravil D.D., Novo Mesto	Rivaroksaban kristalne oblike K in postopek njegove priprave
WO2014102822A2 (en) *	2012-12-26	2014-07-03	Wanbury Ltd.	Aldehyde derivative of substitute oxazolidinones
EP2895176B1 (en)	2012-12-26	2016-10-19	Wanbury Limited	Rivaroxaban intermediate and preparation thereof
US9663505B2 (en)	2013-03-25	2017-05-30	Glenmark Pharmaceuticals Limited	Process for the preparation of rivaroxaban
CN105228996B (zh)	2013-03-25	2017-11-28	百时美施贵宝公司	作为因子XIa抑制剂的含取代唑类的四氢异喹啉
CN104098556B (zh) *	2013-04-09	2019-01-08	浙江九洲药物科技有限公司	一种利伐沙班的合成工艺
WO2014183667A1 (zh) *	2013-05-17	2014-11-20	天津药物研究院	一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途
CN103242307B (zh) *	2013-05-17	2015-08-12	天津药物研究院有限公司	一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途
CA2914040A1 (en) *	2013-06-03	2014-12-11	Bayer Pharma Aktiengesellschaft	Triazolopyridines as thrombin inhibitors for the treatment of thromboembolic diseases
JP2016520110A (ja)	2013-06-03	2016-07-11	バイエルファーマアクチエンゲゼルシャフト	置換ベンゾキサゾール
UY35592A (es)	2013-06-03	2014-12-31	Bayer Pharma AG	Benzoxazoles sustituidos
WO2015011617A1 (en)	2013-07-23	2015-01-29	Ranbaxy Laboratories Limited	Process for the preparation of rivaroxaban
US9598403B2 (en)	2013-08-19	2017-03-21	Amneal Pharmaceuticals Llc	Process for the preparation of rivaroxaban
WO2015104605A1 (en)	2014-01-08	2015-07-16	Wockhardt Limited	A process for preparing rivaroxaban or a pharmaceutically acceptable salt thereof
IN2014CH00290A (et) *	2014-01-23	2015-08-14	Symed Labs Ltd
UY35971A (es)	2014-01-31	2015-07-31	Bristol Myers Squibb Company Una Corporación Del Estado De Delaware	Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
NO2760821T3 (et)	2014-01-31	2018-03-10
WO2015124995A1 (en)	2014-02-19	2015-08-27	Aurobindo Pharma Ltd	Solid dosage forms of rivaroxaban
WO2015155307A1 (en)	2014-04-11	2015-10-15	Sanovel Ilac Sanayi Ve Ticaret A.S.	Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
CN104974149B (zh) *	2014-04-14	2018-05-01	北大方正集团有限公司	一种利伐沙班的制备方法
CN105085371B (zh) *	2014-04-22	2017-06-16	北大方正集团有限公司	(s)‑{1‑(氯甲酸酯基)‑2‑[2‑(1,3‑二氧异吲哚)基]乙基}卤化盐及其制备方法
KR101499867B1 (ko) *	2014-04-22	2015-03-06	에스케이케미칼주식회사	활성 성분 (i) 함유 조성물 및 이의 제조 방법
CN105085370B (zh) *	2014-04-22	2017-04-12	北大方正集团有限公司	(s)‑1‑卤代‑2‑[2‑(1,3‑二氧异吲哚)基]乙基氯甲酸酯及其制备方法
EP2942058A1 (en)	2014-05-09	2015-11-11	Sanovel Ilac Sanayi ve Ticaret A.S.	Pharmaceutical combinations of rivaroxaban and H2-receptor antagonists
CN104031036A (zh) *	2014-05-16	2014-09-10	南通常佑药业科技有限公司	一种利伐沙班的制备方法
KR102412045B1 (ko)	2014-05-22	2022-06-22	놀스 차이나 파마수티칼 컴퍼니., 엘티디.	혈액응고인자 Xa 억제제로서의 히드라지드 화합물
CN103980221B (zh) *	2014-05-26	2016-03-23	山东康美乐医药科技有限公司	4-（硝基苯基）-3-吗啉酮的制备方法及利用其制备利伐沙班的方法
DE102014108210A1 (de)	2014-06-11	2015-12-17	Dietrich Gulba	Rodentizid
WO2015198259A1 (en)	2014-06-26	2015-12-30	Erregierre S.P.A.	Process for the synthesis of rivaroxaban and intermediate for the production thereof
CA2955071A1 (en)	2014-07-15	2016-01-21	Grunenthal Gmbh	Substituted azaspiro(4.5)decane derivatives
TW201607923A (zh)	2014-07-15	2016-03-01	歌林達有限公司	被取代之氮螺環（４．５）癸烷衍生物
CN104086539A (zh) *	2014-07-17	2014-10-08	天津炜捷制药有限公司	一种利伐沙班的制备方法
EP3186246A1 (en)	2014-08-25	2017-07-05	Cipla Limited	Process for the preparation of rivaroxaban
NO2721243T3 (et)	2014-10-01	2018-10-20
CN104356124A (zh) *	2014-10-30	2015-02-18	广东东阳光药业有限公司	噁唑烷酮类化合物及其组合物和用途
CN104402876A (zh) *	2014-11-25	2015-03-11	沈阳药科大学	噁唑烷酮类化合物及其应用
CN104447729A (zh) *	2014-12-05	2015-03-25	广东东阳光药业有限公司	噁唑烷酮类化合物及其在药物中的应用
CN104478866B (zh) *	2014-12-05	2017-07-07	广东东阳光药业有限公司	噁唑烷酮类化合物及其在药物中的应用
CN104478869B (zh) *	2014-12-05	2017-04-12	广东东阳光药业有限公司	噁唑烷酮类化合物及其在药物中的应用
CN104447728B (zh) *	2014-12-05	2017-01-04	广东东阳光药业有限公司	噁唑烷酮类化合物及其在药物中的应用
CN104497008B (zh) *	2014-12-09	2016-11-16	广东东阳光药业有限公司	取代噁唑烷酮类化合物及其使用方法和用途
CN104496978A (zh) *	2014-12-09	2015-04-08	广东东阳光药业有限公司	取代噁唑烷酮类化合物及其使用方法和用途
CN104530029B (zh) *	2014-12-09	2017-04-12	广东东阳光药业有限公司	作为Xa因子抑制剂的杂环化合物及其使用方法和用途
CN104530030A (zh) *	2014-12-10	2015-04-22	广东东阳光药业有限公司	噁唑烷酮类化合物及其在药物中的应用
CN104530080B (zh) *	2014-12-10	2017-01-11	广东东阳光药业有限公司	噁唑烷酮类化合物及其在药物中的应用
CN104530031A (zh) *	2014-12-10	2015-04-22	广东东阳光药业有限公司	噁唑烷酮类化合物及其在药物中的应用
CN105777734A (zh) *	2014-12-22	2016-07-20	常州方楠医药技术有限公司	一种利伐沙班中间体的合成方法
CN104557900A (zh) *	2014-12-23	2015-04-29	中国药科大学	噁唑烷酮类化合物及其制备方法与医药用途
CN105820161A (zh) *	2015-01-08	2016-08-03	常州方楠医药技术有限公司	一种利伐沙班中间体5-羟基甲基噁唑烷酮衍生物的合成方法
TR201501970A2 (en)	2015-02-19	2016-09-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Pharmaceutical combinations of dronedarone.
CN107406440B (zh) *	2015-03-20	2021-05-07	豪夫迈·罗氏有限公司	Bace1抑制剂
WO2016150937A1 (en)	2015-03-25	2016-09-29	Lonza Ltd	Method for preparation of thiophenecarbonyl chlorides
CN104926807B (zh) *	2015-06-04	2017-10-31	沈阳药科大学	一种利伐沙班相关物质“二胺”及其合成方法
CN108026083B (zh)	2015-06-19	2021-08-27	百时美施贵宝公司	作为因子xia抑制剂的二酰胺大环
US10676477B2 (en)	2015-07-29	2020-06-09	Bristol-Myers Squibb Company	Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group
KR102697816B1 (ko)	2015-08-05	2024-08-21	브리스톨-마이어스 스큅 컴퍼니	신규 치환된 글리신 유도된 fxia 억제제
KR101880881B1 (ko) *	2015-11-04	2018-07-20	론자 리미티드	옥살릴 클로라이드를 사용하는 티오펜-2-카보닐 클로라이드의 제조 방법
CA3010726A1 (en)	2016-02-23	2017-08-31	Morgandane Scientific, LLC	Method of treating patients coadministered a factor xa inhibitor and verapamil
JP2019507167A (ja)	2016-03-02	2019-03-14	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	第ｘｉａ因子阻害活性を有するジアミド大員環
WO2018001914A1 (en)	2016-06-28	2018-01-04	Sanovel Ilac Sanayi Ve Ticaret A.S.	Pharmaceutical capsule composition of rivaroxaban
CN106588905A (zh) *	2016-12-13	2017-04-26	重庆英斯凯化工有限公司	一种利伐沙班中间体的制备方法
EP3565552B1 (en)	2017-01-04	2022-05-11	Unichem Laboratories Ltd	An improved process for the preparation of rivaroxaban involving novel intermediate
CN107586291B (zh) *	2017-11-03	2019-08-20	梯尔希（南京）药物研发有限公司	一种利伐沙班代谢物5的合成方法
CN107857739A (zh) *	2017-11-14	2018-03-30	安徽华胜医药科技有限公司	一种氘代利伐沙班关键中间体及其制备方法
CN107857761A (zh) *	2017-11-14	2018-03-30	安徽华胜医药科技有限公司	一种氘代利伐沙班及其制备方法
CN108164519A (zh) *	2017-12-28	2018-06-15	江苏悦兴医药技术有限公司	利伐沙班工艺杂质的合成方法
EP3505160A1 (en)	2017-12-31	2019-07-03	Abdi Ibrahim Ilac Sanayi ve Ticaret A.S.	Preparation of a solid pharmaceutical composition comprising rivaroxaban and production thereof
HU231119B1 (hu)	2018-01-12	2020-11-30	Richter Gedeon Nyrt.	Eljárás 4-(4-aminofenil)morfolin-3-on előállítására
US10828310B2 (en)	2018-02-02	2020-11-10	Bayer Pharma Aktiengesellschaft	Reducing the risk of cardiovascular events
GB201807014D0 (en)	2018-04-30	2018-06-13	Univ Leeds Innovations Ltd	Factor xlla inhibitors
CN108546265A (zh) *	2018-06-22	2018-09-18	苏州中联化学制药有限公司	一种利伐沙班中间体的合成方法
US10722486B2 (en)	2018-08-13	2020-07-28	Morgandane Scientific, LLC	Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil
EP3796915A4 (en)	2018-11-16	2022-01-26	Santa Farma Ilaç Sanayi A.S.	ORAL FORMULATIONS CONTAINING RIVAROXABAN
CN110054621A (zh) *	2019-03-12	2019-07-26	浙江天宇药业股份有限公司	一种利伐沙班中间体的制备方法
CN110615756A (zh) *	2019-06-28	2019-12-27	南京红杉生物科技有限公司	1-(4-硝基苯基)哌啶-2-酮及其合成方法和应用
US11608320B2 (en)	2020-02-02	2023-03-21	Kuwait University	Oxazolidinone hydroxamic acid derivatives
CN111253383A (zh) *	2020-03-27	2020-06-09	南京国星生物技术研究院有限公司	一种利伐沙班的合成方法
CN112159402B (zh) *	2020-10-28	2022-04-05	南京法恩化学有限公司	一种利伐沙班的制备方法
GB202102575D0 (en)	2021-02-23	2021-04-07	Teva Pharmaceutical Industries Ltd	Fixed-dose pharmaceutical compositions
EP4070658A1 (de)	2021-04-06	2022-10-12	BIORoxx GmbH	Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
GB202107722D0 (en)	2021-05-28	2021-07-14	Lunac Therapeutics Ltd	Factor XIIA Inhibitors
CN115260117B (zh) *	2022-08-09	2024-05-28	江苏法安德医药科技有限公司	一种4-(4-氨基苯基)吗啡啉-3-酮的合成方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1035546B (de)	1955-02-16	1958-07-31	Max Ruf	Torbegrenzung fuer Ballspiele
US2811555A (en) *	1955-05-02	1957-10-29	Eastman Kodak Co	Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) *	1965-07-12	1966-10-18	Eastman Kodak Co	Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (fr)	1977-08-26	1979-05-15	Delalande Sa	Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en)	1978-02-10	1978-12-05	E. I. Du Pont De Nemours And Company	5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) *	1978-11-06	1985-02-19	Choay S.A.	Mucopolysaccharides having biological properties, preparation and method of use
US4327725A (en)	1980-11-25	1982-05-04	Alza Corporation	Osmotic device with hydrogel driving member
HU190072B (en) *	1983-03-11	1986-08-28	Biogal Gyogyszergyar,Hu	Process for production of medical preparatives with sinergetic influence
NZ206600A (en)	1983-05-11	1987-01-23	Alza Corp	Osmotic drug delivery device
US4765989A (en)	1983-05-11	1988-08-23	Alza Corporation	Osmotic device for administering certain drugs
ES533097A0 (es)	1983-06-07	1985-08-01	Du Pont	Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
ES2059467T3 (es)	1987-10-21	1994-11-16	Du Pont Merck Pharma	Derivados de aminometil-oxooxazolidinil-etenilbenceno utiles como agentes antibacterianos.
DE3822650A1 (de)	1988-07-05	1990-02-01	Boehringer Mannheim Gmbh	Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4948801A (en)	1988-07-29	1990-08-14	E. I. Du Pont De Nemours And Company	Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5254577A (en) *	1988-07-29	1993-10-19	The Du Pont Merck Pharmaceutical Company	Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
CA2119556C (en)	1991-11-01	2004-07-06	Michael Robert Barbachyn	Substituted aryl- and heteroaryl-phenyloxazolidinones
SK283420B6 (sk)	1992-05-08	2003-07-01	Pharmacia & Upjohn Company	Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5349045A (en) *	1993-01-26	1994-09-20	United States Surgical Corporation	Polymer derived from cyclic amide and medical devices manufactured therefrom
DK0623615T3 (da) *	1993-05-01	1999-12-13	Merck Patent Gmbh	Adhæsionsreceptor-antagonister
US5688792A (en) *	1994-08-16	1997-11-18	Pharmacia & Upjohn Company	Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (de) *	1993-09-23	1995-03-30	Merck Patent Gmbh	Adhäsionsrezeptor-Antagonisten III
DK0807112T3 (da) *	1995-02-03	2001-12-17	Upjohn Co	Antimikrobiel heteroaromatisk ringsubstitueret phenyloxazolidinon
HRP960159A2 (en)	1995-04-21	1997-08-31	Bayer Ag	Benzocyclopentane oxazolidinones containing heteroatoms
DE19524765A1 (de) *	1995-07-07	1997-01-09	Boehringer Mannheim Gmbh	Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
NZ315469A (en)	1995-09-01	2000-01-28	Upjohn Co	Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings
DE69631347T2 (de)	1995-09-15	2004-10-07	Upjohn Co	Aminoaryl oxazolidinone n-oxide
DE19601264A1 (de) *	1996-01-16	1997-07-17	Bayer Ag	Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de)	1996-02-06	1997-08-07	Bayer Ag	Neue substituierte Oxazolidinone
HRP970049A2 (en) *	1996-02-06	1998-04-30	Bayer Ag	New heteroaryl oxazolidinones
GB9614238D0 (en)	1996-07-06	1996-09-04	Zeneca Ltd	Chemical compounds
ES2250283T3 (es)	1996-07-15	2006-04-16	Sankyo Company Limited	Uso de cs-866 (olmesartan) en la preparacion de un medicamento para el tratamiento de la arteriosclerosis.
US6273913B1 (en)	1997-04-18	2001-08-14	Cordis Corporation	Modified stent useful for delivery of drugs along stent strut
CA2288750A1 (en)	1997-05-30	1998-12-03	Pharmacia & Upjohn Company	Oxazolidinone antibacterial agents having a thiocarbonyl functionality
AU729745B2 (en)	1997-07-11	2001-02-08	Pharmacia & Upjohn Company	Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
DE19730847A1 (de)	1997-07-18	1999-01-28	Bayer Ag	Tricyclisch substituierte Oxazolidinone
GB9715894D0 (en)	1997-07-29	1997-10-01	Zeneca Ltd	Heterocyclic derivatives
DE19747261A1 (de)	1997-10-25	1999-04-29	Bayer Ag	Osmotisches Arzneimittelfreisetzungssystem
KR20010031953A (ko)	1997-11-12	2001-04-16	로렌스 티. 마이젠헬더	옥사졸리디논 유도체 및 제약 조성물
US6083967A (en)	1997-12-05	2000-07-04	Pharmacia & Upjohn Company	S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
DE19755268A1 (de) *	1997-12-12	1999-06-17	Merck Patent Gmbh	Benzamidinderivate
DE19802239A1 (de)	1998-01-22	1999-07-29	Bayer Ag	Neue mit Bicyclen substituierte Oxazolidinone
WO1999037630A1 (en)	1998-01-23	1999-07-29	Versicor, Inc.	Oxazolidinone combinatorial libraries, compositions and methods of preparation
JP4676613B2 (ja)	1998-01-27	2011-04-27	アベンティス・ファーマスーティカルズ・インコーポレイテツド	置換オキソアザヘテロシクリルＸａ因子阻害剤
DE19805117A1 (de)	1998-02-09	1999-08-12	Bayer Ag	Neue Oxazolidinone mit azolhaltigen Tricyclen
US20010029351A1 (en)	1998-04-16	2001-10-11	Robert Falotico	Drug combinations and delivery devices for the prevention and treatment of vascular disease
DE69902526T2 (de) *	1998-05-18	2003-04-03	Pharmacia & Upjohn Co., Kalamazoo	Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate
DE19842753A1 (de)	1998-09-18	2000-03-23	Bayer Ag	Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6413981B1 (en)	1999-08-12	2002-07-02	Ortho-Mcneil Pharamceutical, Inc.	Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
PE20010851A1 (es)	1999-12-14	2001-08-17	Upjohn Co	Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
PL356478A1 (en)	1999-12-21	2004-06-28	Pharmacia & Upjohn Company	Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de)	1999-12-24	2001-07-05	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
KR20020063609A (ko)	1999-12-28	2002-08-03	아지노모토 가부시키가이샤	아스파탐 유도체 결정
DE10105989A1 (de)	2001-02-09	2002-08-14	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
DE10110438A1 (de)	2001-03-05	2002-09-19	Bayer Ag	Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110754A1 (de)	2001-03-07	2002-09-19	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10115945A1 (de)	2001-03-30	2002-10-02	Bayer Ag	Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115922A1 (de)	2001-03-30	2002-10-10	Bayer Ag	Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10129725A1 (de)	2001-06-20	2003-01-02	Bayer Ag	Kombinationstherapie substituierter Oxazolidinone
DE10134481A1 (de)	2001-07-16	2003-01-30	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10152460A1 (de)	2001-10-24	2003-05-08	Bayer Ag	Stents
DE10238113A1 (de)	2001-12-11	2003-06-18	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
US20030161882A1 (en)	2002-02-01	2003-08-28	Waterman Kenneth C.	Osmotic delivery system
DE10300111A1 (de)	2003-01-07	2004-07-15	Bayer Healthcare Ag	Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de)	2003-11-27	2005-06-23	Bayer Healthcare Ag	Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de)	2004-01-15	2005-08-04	Bayer Healthcare Ag	Herstellverfahren
DE102004062475A1 (de)	2004-12-24	2006-07-06	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en)	2005-01-31	2006-08-02	Bayer Health Care Aktiengesellschaft	Prevention and treatment of thromboembolic disorders
ES2586125T3 (es)	2005-02-14	2016-10-11	Epitopix, Llc	Polipéptidos de Staphylococcus aureus y métodos de uso
DE102005045518A1 (de)	2005-09-23	2007-03-29	Bayer Healthcare Ag	2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
RU2429236C2 (ru)	2005-10-04	2011-09-20	Байер Шеринг Фарма Акциенгезельшафт	Новая полиморфная форма и аморфная форма 5-хлор-n-({(5s)-2-оксо-3-[4-(3-оксо-4-морфолинил)-фенил]-1, 3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида
DE102005047561A1 (de)	2005-10-04	2007-04-05	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005047558A1 (de)	2005-10-04	2008-02-07	Bayer Healthcare Ag	Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005048824A1 (de)	2005-10-10	2007-04-12	Bayer Healthcare Ag	Behandlung und Prophylaxe von Mikroangiopathien
KR101378695B1 (ko) *	2007-04-18	2014-03-31	삼성전자주식회사	통신 시스템에서의 훈련 시퀀스 코드 생성 방법 및 장치

1999
- 1999-12-24 DE DE19962924A patent/DE19962924A1/de not_active Withdrawn
2000
- 2000-11-29 HN HN2000000267A patent/HN2000000267A/es unknown
- 2000-12-11 NZ NZ519730A patent/NZ519730A/en not_active IP Right Cessation
- 2000-12-11 EP EP00993610A patent/EP1261606B1/de not_active Expired - Lifetime
- 2000-12-11 DE DE122009000014C patent/DE122009000014I1/de active Pending
- 2000-12-11 EE EEP200200341A patent/EE05169B1/et active Protection Beyond IP Right Term
- 2000-12-11 SG SG200403830-3A patent/SG130939A1/en unknown
- 2000-12-11 CN CNB008189668A patent/CN1262551C/zh not_active Expired - Lifetime
- 2000-12-11 TR TR2004/01314T patent/TR200401314T2/xx unknown
- 2000-12-11 IL IL14989600A patent/IL149896A0/xx active Protection Beyond IP Right Term
- 2000-12-11 EP EP04027037.3A patent/EP1526132B1/de not_active Expired - Lifetime
- 2000-12-11 KR KR1020077020537A patent/KR20070094672A/ko not_active Application Discontinuation
- 2000-12-11 CN CN2006100819193A patent/CN1900074B/zh not_active Expired - Lifetime
- 2000-12-11 CZ CZ20022202A patent/CZ301432B6/cs not_active IP Right Cessation
- 2000-12-11 SI SI200031079T patent/SI1526132T1/sl unknown
- 2000-12-11 BR BRPI0017050-0A patent/BR0017050B1/pt active IP Right Grant
- 2000-12-11 UA UA2002076161A patent/UA73339C2/uk unknown
- 2000-12-11 KR KR1020027008172A patent/KR100804932B1/ko active IP Right Review Request
- 2000-12-11 DE DE50009607T patent/DE50009607D1/de not_active Expired - Lifetime
- 2000-12-11 AT AT00993610T patent/ATE289605T1/de active
- 2000-12-11 RU RU2002120456/04A patent/RU2297415C2/ru active Protection Beyond IP Right Term
- 2000-12-11 PT PT00993610T patent/PT1261606E/pt unknown
- 2000-12-11 CN CNB2005101271139A patent/CN100549008C/zh not_active Expired - Lifetime
- 2000-12-11 DK DK00993610T patent/DK1261606T3/da active
- 2000-12-11 JP JP2001549389A patent/JP4143297B2/ja not_active Expired - Lifetime
- 2000-12-11 NZ NZ537058A patent/NZ537058A/en not_active IP Right Cessation
- 2000-12-11 SK SK908-2002A patent/SK287272B6/sk not_active IP Right Cessation
- 2000-12-11 HU HU0203902A patent/HU226522B1/hu active Protection Beyond IP Right Term
- 2000-12-11 PT PT40270373T patent/PT1526132E/pt unknown
- 2000-12-11 WO PCT/EP2000/012492 patent/WO2001047919A1/de active Application Filing
- 2000-12-11 US US10/181,051 patent/US7157456B2/en not_active Expired - Lifetime
- 2000-12-11 KR KR1020077008192A patent/KR20070044075A/ko not_active Application Discontinuation
- 2000-12-11 CA CA002396561A patent/CA2396561C/en not_active Expired - Lifetime
- 2000-12-11 PL PL355665A patent/PL200413B1/pl unknown
- 2000-12-11 TR TR2002/01636T patent/TR200201636T2/xx unknown
- 2000-12-11 AU AU28414/01A patent/AU775126C/en not_active Expired
- 2000-12-11 MX MXPA02006241A patent/MXPA02006241A/es active IP Right Grant
- 2000-12-11 DK DK04027037.3T patent/DK1526132T3/da active
- 2000-12-11 SI SI200030679T patent/SI1261606T1/xx unknown
- 2000-12-11 ES ES00993610T patent/ES2237497T3/es not_active Expired - Lifetime
- 2000-12-11 ES ES04027037.3T patent/ES2457021T3/es not_active Expired - Lifetime
- 2000-12-11 PL PL382243A patent/PL201121B1/pl unknown
- 2000-12-18 AR ARP000106733A patent/AR032436A1/es active IP Right Grant
- 2000-12-19 GT GT200000216A patent/GT200000216A/es unknown
- 2000-12-20 TW TW089127307A patent/TWI226330B/zh active
- 2000-12-20 TW TW083120747A patent/TWI277615B/zh not_active IP Right Cessation
- 2000-12-20 DO DO2000000114A patent/DOP2000000114A/es unknown
- 2000-12-21 SV SV2000000245A patent/SV2002000245A/es active IP Right Grant
- 2000-12-22 PE PE2000001388A patent/PE20010963A1/es not_active IP Right Cessation
- 2000-12-22 MY MYPI20006170A patent/MY140488A/en unknown
- 2000-12-22 CO CO00097415A patent/CO5251440A1/es active IP Right Grant
2002
- 2002-05-27 ZA ZA200204188A patent/ZA200204188B/en unknown
- 2002-06-07 CU CU20020114A patent/CU23208A3/es unknown
- 2002-06-14 BG BG106825A patent/BG65683B1/bg unknown
- 2002-06-21 NO NO20023043A patent/NO323699B1/no not_active IP Right Cessation
- 2002-06-21 MA MA26708A patent/MA25646A1/fr unknown
- 2002-07-23 HR HR20020617A patent/HRP20020617B1/xx not_active IP Right Cessation
2004
- 2004-01-20 HK HK04100440A patent/HK1057556A1/xx not_active IP Right Cessation
- 2004-01-20 HK HK06112529.9A patent/HK1092140A1/xx not_active IP Right Cessation
- 2004-10-13 CU CU20040221A patent/CU23423B7/es unknown
- 2004-10-13 AU AU2004218729A patent/AU2004218729A1/en not_active Withdrawn
- 2004-12-10 JP JP2004358908A patent/JP5190173B2/ja not_active Expired - Lifetime
2006
- 2006-07-18 HR HRP20060251AA patent/HRP20060251B1/hr not_active IP Right Cessation
- 2006-07-27 US US11/460,529 patent/US7592339B2/en not_active Expired - Fee Related
2007
- 2007-02-20 NO NO20070981A patent/NO20070981L/no not_active Application Discontinuation
- 2007-07-17 HK HK07107638.6A patent/HK1103235A1/xx not_active IP Right Cessation
- 2007-10-31 US US11/932,082 patent/US7576111B2/en not_active Expired - Fee Related
2008
- 2008-01-11 DO DO2008000001A patent/DOP2008000001A/es unknown
- 2008-02-07 US US12/027,553 patent/US7585860B2/en not_active Expired - Fee Related
- 2008-11-19 LU LU91497C patent/LU91497I2/xx unknown
- 2008-11-25 NL NL300370C patent/NL300370I2/nl unknown
- 2008-12-02 CY CY200800019C patent/CY2008019I1/el unknown
- 2008-12-04 LT LTPA2008018C patent/LTC1261606I2/lt unknown
- 2008-12-10 BE BE2008C046C patent/BE2008C046I2/fr unknown
- 2008-12-11 FR FR08C0051C patent/FR08C0051I2/fr active Active
2009
- 2009-01-08 NO NO2009001C patent/NO2009001I1/no not_active IP Right Cessation
- 2009-06-30 US US12/494,879 patent/US8129378B2/en not_active Expired - Fee Related
2010
- 2010-04-22 IL IL205242A patent/IL205242A/en unknown
2012
- 2012-01-27 US US13/360,107 patent/US8530505B2/en not_active Expired - Fee Related
- 2012-06-22 UY UY0001034152A patent/UY34152A/es not_active Application Discontinuation
2013
- 2013-08-07 US US13/961,264 patent/US8822458B2/en not_active Expired - Fee Related
2014
- 2014-05-29 CY CY20141100383T patent/CY1115117T1/el unknown
- 2014-07-21 US US14/336,379 patent/US20150166568A1/en not_active Abandoned
2021
- 2021-02-25 NO NO2021009C patent/NO2021009I1/no unknown

Also Published As

Publication number	Publication date
MXPA02006241A (es)	2003-01-28
DE19962924A1 (de)	2001-07-05
TWI277615B (de)	2007-04-01
PT1526132E (pt)	2014-04-15
SI1526132T1 (sl)	2014-07-31
CU23423B7 (es)	2009-09-08
DOP2000000114A (es)	2002-07-15
US7585860B2 (en)	2009-09-08
US8530505B2 (en)	2013-09-10
US20130316999A1 (en)	2013-11-28
KR20070044075A (ko)	2007-04-26
CA2396561C (en)	2008-10-14
BG106825A (en)	2003-02-28
HUP0203902A2 (hu)	2003-03-28
NO323699B1 (no)	2007-06-25
HRP20020617A2 (en)	2004-12-31
EP1261606B1 (de)	2005-02-23
CN1262551C (zh)	2006-07-05
NO2009001I1 (no)	2009-02-02
HK1057556A1 (en)	2004-04-08
AU2841401A (en)	2001-07-09
CN1900074A (zh)	2007-01-24
DK1526132T3 (da)	2014-06-16
LU91497I2 (fr)	2009-01-19
DE50009607D1 (de)	2005-03-31
ES2237497T3 (es)	2005-08-01
HUP0203902A3 (en)	2003-07-28
AR032436A1 (es)	2003-11-12
CY1115117T1 (el)	2016-12-14
SG130939A1 (en)	2007-04-26
HRP20060251B1 (hr)	2016-08-12
PT1261606E (pt)	2005-07-29
US7157456B2 (en)	2007-01-02
CN1772751A (zh)	2006-05-17
RU2002120456A (ru)	2004-01-10
EE200200341A (et)	2003-10-15
HN2000000267A (es)	2001-06-13
NL300370I1 (nl)	2009-02-02
HK1103235A1 (en)	2007-12-14
US20060258724A1 (en)	2006-11-16
RU2297415C2 (ru)	2007-04-20
PE20010963A1 (es)	2001-11-10
IL205242A (en)	2011-12-29
NO20023043D0 (no)	2002-06-21
KR20020067569A (ko)	2002-08-22
UY34152A (es)	2013-02-28
FR08C0051I2 (fr)	2009-12-18
KR20070094672A (ko)	2007-09-20
SV2002000245A (es)	2002-01-15
HU226522B1 (en)	2009-03-30
US7576111B2 (en)	2009-08-18
PL200413B1 (pl)	2009-01-30
LU91497I9 (et)	2019-01-02
LTC1261606I2 (lt)	2021-05-10
TW200422299A (en)	2004-11-01
WO2001047919A1 (de)	2001-07-05
US8129378B2 (en)	2012-03-06
UA73339C2 (en)	2005-07-15
CN100549008C (zh)	2009-10-14
AU775126B2 (en)	2004-07-15
HRP20020617B1 (en)	2006-09-30
TR200201636T2 (tr)	2002-10-21
NO20023043L (no)	2002-08-14
ZA200204188B (en)	2003-05-27
BR0017050B1 (pt)	2012-06-12
PL355665A1 (en)	2004-05-04
CA2396561A1 (en)	2001-07-05
AU775126C (en)	2005-09-01
NL300370I2 (nl)	2009-05-06
HRP20060251A2 (en)	2006-12-31
DE122009000014I1 (de)	2009-11-05
US20080090815A1 (en)	2008-04-17
CZ301432B6 (cs)	2010-03-03
NZ537058A (en)	2006-04-28
US8822458B2 (en)	2014-09-02
SK287272B6 (sk)	2010-05-07
EP1526132B1 (de)	2014-03-12
SK9082002A3 (en)	2003-04-01
BE2008C046I2 (et)	2019-12-16
NO2021009I1 (no)	2021-02-25
JP5190173B2 (ja)	2013-04-24
US20030153610A1 (en)	2003-08-14
IL149896A0 (en)	2002-11-10
US20130005701A1 (en)	2013-01-03
EP1261606A1 (de)	2002-12-04
US20100137274A1 (en)	2010-06-03
DOP2008000001A (es)	2010-01-15
US20150166568A1 (en)	2015-06-18
LTPA2008018I1 (lt)	2021-04-12
GT200000216A (es)	2002-06-12
WO2001047919A9 (de)	2002-12-19
MA25646A1 (fr)	2002-12-31
ATE289605T1 (de)	2005-03-15
TWI226330B (en)	2005-01-11
ES2457021T3 (es)	2014-04-24
EP1526132A2 (de)	2005-04-27
NO20070981L (no)	2002-08-14
JP2005068164A (ja)	2005-03-17
HK1092140A1 (en)	2007-02-02
CN1900074B (zh)	2012-07-11
NZ519730A (en)	2005-02-25
TR200401314T2 (tr)	2004-08-23
CY2008019I2 (el)	2009-11-04
JP4143297B2 (ja)	2008-09-03
FR08C0051I1 (et)	2008-10-17
SI1261606T1 (et)	2005-08-31
MY140488A (en)	2009-12-31
DK1261606T3 (da)	2005-05-09
NO2009001I2 (et)	2010-05-11
IL205242A0 (en)	2011-07-31
US7592339B2 (en)	2009-09-22
BR0017050A (pt)	2002-11-05
JP2003519141A (ja)	2003-06-17
AU2004218729A1 (en)	2004-11-04
CU23208A3 (es)	2007-06-20
BG65683B1 (bg)	2009-06-30
KR100804932B1 (ko)	2008-02-20
EP1526132A3 (de)	2005-08-31
CY2008019I1 (el)	2009-11-04
PL201121B1 (pl)	2009-03-31
US20080200674A1 (en)	2008-08-21
CN1434822A (zh)	2003-08-06
CO5251440A1 (es)	2003-02-28
CZ20022202A3 (cs)	2002-11-13

Publication	Publication Date	Title
EE200200341A (et)	2003-10-15	Asendatud oksasolidinoonid ja nende kasutamine
EE200200251A (et)	2003-06-16	Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
EE200200175A (et)	2003-04-15	Asendatud 2-tio-3,5-ditsüano-4-arüül-6-aminopüridiinid ja nende kasutamine
ID26056A (id)	2000-11-23	Popok sekali pakai
ID26389A (id)	2000-12-21	Popok sekali pakai
DE60044873D1 (de)	2010-10-07	Orientierte biopolymermembrane
NO20021116D0 (no)	2002-03-06	Ny sammensetning
IS6120A (is)	2001-10-22	Lyfjablanda
ID25977A (id)	2000-11-16	Popok sekali pakai
ID24555A (id)	2000-07-27	Popok sekali pakai
ID23076A (id)	2000-02-03	Popok sekali pakai
EE200100373A (et)	2002-10-15	Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
ID26608A (id)	2001-01-25	Komposit-komposit polimer-pigmen
DE10084676T1 (de)	2003-04-30	Einmallanzettvorrichtung
NO20021115D0 (no)	2002-03-06	Ny sammensetning
ID27776A (id)	2001-04-26	Bahan dengan efek antidepresan
ID23083A (id)	2000-02-03	Popok sekali pakai
DE60043058D1 (de)	2009-11-12	Dentalwerkstoffe
DE69943245D1 (de)	2011-04-14	Gaserzeugende zusammensetzung
ID24782A (id)	2000-08-10	Popok sekali pakai
ID25571A (id)	2000-10-19	Popok sekali pakai
DE60032898D1 (de)	2007-02-22	Arylthiazolidindion- und aryloxazolidinderivate
DK199901730A (da)	2000-12-23	Ny Sammensætning
DE60020682D1 (de)	2005-07-14	Resorcinenthaltende zusammensetzung
DE19983890T1 (de)	2002-03-07	Ventiltaktgebungsjustiereinrichtung

Legal Events

Date	Code	Title	Description
2003-12-15	HB1A	Correction of owner name or address
2004-10-15	GB1A	Change in the ownership or in the address of the owner
2009-06-15	GB1A	Change in the ownership or in the address of the owner
2009-10-15	AA1Y	Spc filed	Free format text: PRODUCT NAME: XARELTO-RIVAROXABAN Spc suppl protection certif: C20090004 Filing date: 20090812
2009-10-15	FG1Y	Spc granted	Free format text: PRODCUT NAME: XARELTO-RIVAROXABAN Spc suppl protection certif: C20090004 00025 Filing date: 20090812 Extension date: 20230930
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2013-02-15	GB1A	Change in the ownership or in the address of the owner
2021-08-16	SPCE	Request for extension of supplementary protection certificate filed [paediatric extension]	Free format text: PRODUCT NAME: XARELTO-RIVAROXABAN; AUTHORISATION NUMBER/DATE: EMA/207785/2021, 13.04.2021 Spc suppl protection certif: C20090004 00025 Extension date: 20240402
2023-08-15	SPCT	Party data change related to a supplementary protection certificate	Free format text: PARTY DATA CHANGE RELATED TO A GRANTED SPC Spc suppl protection certif: 00025